AI in Life Science Analytics Market Size & Share 2024 – 2032

AI in Life Science Analytics Market Size

AI in Life Science Analytics Market size was valued at USD 1.3 billion in 2023 and is expected to exhibit growth at a CAGR of 11.5% from 2024 to 2032. The life science analytics market, driven by AI technologies, is experiencing significant growth due to the increasing demand for advanced data analytics to optimize pharmaceutical and biotechnology research and development processes.

AI-driven analytics are transforming the life sciences sector by enabling more accurate data interpretation, enhancing drug discovery processes, and optimizing clinical trials. For instance, automated machine learning algorithms are being used to predict patient outcomes and identify potential drug candidates more efficiently. Additionally, natural language processing (NLP) tools are being leveraged to analyze unstructured data from scientific literature and electronic health records, aiding in the identification of novel biomarkers and therapeutic targets.
 

The adoption of AI in life sciences is further fueled by the increasing volume of data generated from genomics, proteomics, and other omics technologies, which require sophisticated analytical tools to derive actionable insights. Pharmaceutical companies are investing heavily in AI to expedite drug development timelines and reduce costs associated with clinical trials.
 

Moreover, AI is being utilized to personalize medicine by predicting patient responses to different treatments, thereby improving patient outcomes and reducing adverse effects. Regulatory bodies, such as the FDA, are also encouraging the integration of AI in drug development processes by providing guidelines for its use, which is fostering greater adoption of these technologies.
 

AI in life science analytics refers to the application of artificial intelligence technologies to analyze vast and complex datasets in the life sciences field. This includes using machine learning, natural language processing, and other AI tools to enhance drug discovery, optimize clinical trials, predict patient outcomes, and analyze genomic and proteomic data. AI-driven analytics enable more precise, efficient, and cost-effective decision-making in pharmaceutical research and healthcare.
 

AI in Life Science Analytics Market Trends

The rising demand for efficient drug discovery is a major driver for the adoption of AI in the life science analytics market. Traditional drug discovery processes are time-consuming and expensive, often taking over a decade and costing billions of dollars to bring a new drug to market. With the increasing complexity of diseases and the need for personalized medicine, there is a growing demand for more efficient and cost-effective drug discovery methods.
 

• AI technologies, particularly machine learning and deep learning, have emerged as transformative tools in this space. They enable the rapid analysis of vast datasets, including genomic data, chemical libraries, and clinical trial data, to identify potential drug candidates more quickly and accurately than traditional methods.
   
• Recent instances highlight the significant impact of AI on drug discovery. For example, in 2023, Insilico Medicine, an AI-driven drug discovery company, advanced its AI-discovered drug candidate for idiopathic pulmonary fibrosis into clinical trials, marking a milestone in AI's potential to expedite drug development. Similarly, Ex Scientia, another AI-focused company, reported that its AI-designed drug for obsessive-compulsive disorder reached Phase 1 clinical trials in less than 12 months, significantly faster than the industry average of 4-6 years. These examples demonstrate AI's capability to shorten drug discovery timelines and reduce associated costs, addressing one of the biggest challenges in the pharmaceutical industry.
• AI's ability to analyze complex biological data, predict drug-target interactions, and simulate clinical outcomes makes it an indispensable tool for modern drug discovery. Companies are increasingly investing in AI platforms to enhance their drug discovery pipelines, as evidenced by significant collaborations and partnerships. For instance, Pfizer partnered with IBM Watson to utilize AI for immuno-oncology research, while Bayer collaborated with Recursion Pharmaceuticals to leverage AI for discovering new treatments in fibrosis.
   

AI in Life Science Analytics Market Analysis

Based on component, the market is classified into services, software, and hardware. The services segment generated the highest revenue of USD 571.6 million in 2023.
 

• This growth is driven by the rising demand for AI implementation and integration services, the complexity of AI technologies, and the need for customized and personalized solutions. Many organizations are increasingly aware of the benefits AI can bring to improving operational efficiency, enhancing customer engagement, and making better decisions. However, many of these organizations lack the in-house expertise to effectively implement and integrate AI solutions. As a result, there is a growing demand for AI service providers who offer consulting, implementation, customization, and integration services. For example, companies like IBM Watson provide AI-as-a-Service platforms, which give businesses access to pre-built AI models and tools for various applications, such as predictive analytics and virtual assistants. These platforms make it easier for businesses to adopt AI by offering ready-to-use solutions and technical support.
   
• Additionally, businesses are looking for AI solutions that are tailored to their specific needs and industry standards. AI service providers offer customization services to align AI capabilities with a company's objectives, workflows, and regulatory requirements. As a result, service providers play a critical role in bridging the gap between AI technology and its practical application, further fueling the growth of the market.
   

Based on application, the AI in life science analytics market is categorized into sales and marketing support, supply chain analytics, research and development, and other applications. The sales and marketing support segment generated the highest revenue of USD 516.4 million in 2023.
 

• This growth is driven by the rising adoption of AI-driven solutions that boost sales effectiveness, customer engagement, and market intelligence within the life sciences sector. AI enables companies to tailor customer interactions and strategies by leveraging individual preferences, behaviors, and historical data. By analyzing vast datasets—including customer profiles, purchasing patterns, and market trends—advanced analytics and AI algorithms facilitate audience segmentation and the creation of highly targeted marketing campaigns.
   

Based on deployment, the AI in life science analytics market is bifurcated into cloud-based and on-premises. The cloud-based segment dominated the market in 2023 and is anticipated to reach USD 2 billion by 2032.
 

• This growth is driven by the cloud’s scalability, flexibility, and cost-effectiveness. Cloud service providers offer AI-specific tools and services that simplify the development, training, and deployment of machine learning models in the life sciences sector. These platforms give users access to pre-built AI algorithms, model development frameworks, and automated workflows, making the AI lifecycle management process more efficient.
   
• For example, Microsoft Azure provides affordable AI solutions for life sciences, including AI-powered analytics and machine learning tools. Azure's flexible pricing and comprehensive cloud services help organizations optimize their research budgets and improve operational efficiency through scalable AI deployments.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end-use, the AI in life science analytics market is segmented into pharmaceutical and biotech companies, medical device manufacturers, contract research organizations, and other end-users. The pharmaceutical and biotech companies segment dominated the market in 2023 and is anticipated to reach USD 1.7 billion by 2032.
 

• AI is helping pharmaceutical companies adopt precision medicine by analyzing patient data, genetic profiles, and biomarkers to create personalized treatment plans based on individual characteristics and the complexity of diseases. For example, Insilico Medicine uses AI to discover new drug candidates and optimize molecular structures, speeding up the drug discovery process.
   
• Their AI-driven platforms help identify promising compounds, streamline preclinical testing, and foster collaborative research partnerships to meet unmet medical needs and improve patient outcomes. Additionally, various government organizations are working to ensure the safe use of AI in the pharmaceutical industry. For instance, in March 2024, the WHO released a discussion paper to explore the increasing use of AI in every step of vaccine and medicine development and production.
   

North America AI in life science analytics market accounted for USD 490.0 million market revenue in 2023 and is anticipated to grow at CAGR of 10.8% between 2024 and 2032.
 

• This growth is primarily driven by the increasing adoption of AI to enhance drug discovery, clinical trials, and personalized medicine. Companies are leveraging AI to analyze vast datasets, uncover insights, and accelerate research and development. For example, Pfizer uses AI to predict potential drug interactions and optimize clinical trial designs, reducing time and costs.  
   
• Additionally, partnerships between tech companies and pharmaceutical firms, such as the collaboration between IBM Watson Health and Pfizer, are becoming more common to integrate AI tools into research processes, further boosting the market's expansion in the region.
   

U.S. AI in life science analytics market accounted for USD 449.2 million market revenue in 2023 and is estimated to hold substantial share between 2024 to 2032.
 

• The AI in the life sciences market in the U.S. is growing due to the rising application of AI across different areas of life sciences. For example, in March 2023, NVIDIA introduced new generative AI cloud services tailored to enhance AI foundation models.
   
• These services aim to speed up the development of proteins and therapeutics while advancing research in fields like genomics, chemistry, biology, and molecular dynamics.
   

UK AI in life science analytics market is projected to grow remarkably in the coming years.
 

• The use of AI is expanding as organizations seek to leverage advanced analytics to drive innovation. For instance, Benevolent AI is utilizing AI to identify new drug candidates and uncover insights into complex diseases. Additionally, the UK's National Health Service (NHS) is implementing AI-driven tools to enhance patient care and streamline clinical workflows.
   
• Partnerships between tech companies and life science firms, such as the collaboration between AstraZeneca and IBM Watson, are also fueling growth by integrating AI into research and development processes.
   

Japan holds a dominant position in the Asia Pacific AI in life science analytics market.
 

• Japan's market is witnessing rapid growth, driven by advancements in technology and increasing investments in research. Companies are integrating AI to enhance drug development, genomics research, and clinical trials. For example, Takeda Pharmaceutical is utilizing AI to accelerate drug discovery and optimize clinical trial processes.
   
• Additionally, partnerships between Japanese tech firms and global life science companies are expanding, such as the collaboration between Fujitsu and Astellas Pharma to leverage AI for improving patient outcomes and developing innovative therapies. These trends highlight Japan's commitment to advancing life science research through AI innovations.
   

AI in Life Science Analytics Market Share

The market is characterized by the presence of several key players and a focus on technological innovation and strategic partnerships. Companies are investing in AI-driven analytics platforms that provide deeper insights into life science.
 

AI in Life Science Analytics Market Companies

Prominent players operating in the AI in Life Science analytics industry include:

• AiCure LLC
• Atomwise
• Axtria
• Databricks
• IBM Corporation
• Indegene
• Lexalytics
• Nuance communications
• NuMedii
• Oracle Corporation
• Saama
• SAS Institute, Inc.
• Sisense
• Sorcero
• Tempus AI
   

AI in Life Science Analytics Industry News:

• In June 2024, Medidata introduced Clinical Data Studio, a comprehensive platform that consolidates data from both Medidata and external sources. This technology enables stakeholders to manage data quality effectively, expedite trial processes, and make faster decisions by providing a complete view of data and risk strategies. AI plays a crucial role in detecting potential issues and safety signals.
   
• In September 2023, SAS launched SAS Health, a new AI and analytics platform designed for health insurers, providers, and public health agencies. This solution provides these organizations with the flexibility and agility needed to foster health innovation, thereby enhancing health outcomes and patient experiences.
   

The AI in life science analytics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Services
• Software
• Hardware

Market, By Application

• Sales and marketing support
• Supply chain analytics
• Research and development
• Other applications

Market, By Deployment

• Cloud-based
• On-premises

Market, By End-use

• Pharmaceutical and biotech companies
• Medical device manufacturers
• Contract research organizations
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa